Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
12/10/2026 23:20
BRIEF-Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update Oct 12 (Reuters) - Oncolytics Biotech Inc ONCY.O:
ONCOLYTICS BIOTECH® SECURES PATENT PROTECTION TO LATE 2040S AND PROVIDES INTELLECTUAL PROPERTY PORTFOLIO UPDATE
ONCOLYTICS BIOTECH - NEW METHOD OF USE PATENT FOR PELAREOREP ISSUED IN SEVERAL COUNTRIES; U.S. ISSUANCE EXPECTED SOON
ONCOLYTICS BIOTECH - COMPANY EXPECTS TO ADD NEW COMPOSITION OF MATTER PATENT FOR NEXT GENERATION PELAREOREP
ONCOLYTICS BIOTECH - THREE PATENT APPLICATIONS PENDING; ONE TO BE CONVERTED TO TRACK ONE THIS QUARTER
ONCOLYTICS BIOTECH - NEW METHOD OF USE PATENTS EXPECTED TO PROVIDE PROTECTION INTO LATE 2040S
Source text: ID:nGNX8GgjsK
Further company coverage: ONCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer
Brief: Oncolytics Biotech Announces New US Patent For Pelareorep Manufacturing Process
Brief: Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer